AXS Stock Recent News

Axis Capital (AXS) came out with quarterly earnings of $3.17 per share, beating the Zacks Consensus Estimate of $2.64 per share. This compares to earnings of $2.57 per share a year ago.

PEMBROKE, Bermuda--(BUSINESS WIRE)---- $AXS #insurance--AXIS Capital Holdings Limited ("AXIS Capital" or "AXIS" or "the Company") (NYSE: AXS) today announced financial results for the first quarter ended March 31, 2025. Commenting on the first quarter 2025 financial results, Vince Tizzio, President and CEO of AXIS Capital said: "AXIS delivered another strong quarter of consistent, profitable performance as we continued to lean into our specialty underwriting value proposition, while helping our customers navigate.

PEMBROKE, Bermuda--(BUSINESS WIRE)---- $AXS #insurance--AXIS Capital Holdings Limited (“AXIS Capital” or “AXIS” or the “Company”) (NYSE: AXS) and Enstar Group Limited (“Enstar”) (Nasdaq: ESGR) announced today that they have completed a loss portfolio transfer (“LPT”) transaction, covering reinsurance segment reserves predominantly attributable to casualty portfolios related to 2021 and prior underwriting years. The LPT reinsurance agreement covers reinsurance segment reserves totalling $3.1 billion at September 30.

Axis Capital (AXS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Investors interested in stocks from the Insurance - Property and Casualty sector have probably already heard of Axis Capital (AXS) and Chubb (CB). But which of these two companies is the best option for those looking for undervalued stocks?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

NEW YORK , April 8, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Axsome Therapeutics, Inc. (NASDAQ: AXSM)  breached their fiduciary duties to shareholders.  According to a federal securities lawsuit, Insiders at Axsome caused the company to misrepresent or fail to disclose (i) Axsome's chemistry, manufacturing, and control ("CMC") practices were deficient with respect to AXS-07 and its manufacturing process; (ii) as a result, Axsome was unlikely to submit the AXS-07 NDA on its initially represented timeline; (iii) the foregoing CMC issues remained unresolved at the time that the FDA reviewed the AXS-07 NDA; (iv) accordingly, the FDA was unlikely to approve the AXS-07 NDA; (v) as a result of all the foregoing, Axsome had overstated AXS-07's regulatory and commercial prospects; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

PEMBROKE, Bermuda--(BUSINESS WIRE)---- $AXS #insurance--AXIS Capital Holdings Limited (“AXIS Capital” or the “Company”) (NYSE: AXS) today announced that it expects to release financial results for the first quarter ended March 31, 2025 on Wednesday, April 30, 2025 after the close of the financial markets. Vince Tizzio, President and Chief Executive Officer, and Peter Vogt, Chief Financial Officer, will host an investor teleconference, including a question and answer period, on Thursday, May 1, 2025 at 8:30 a.m. ET.

Axsome's AXS-05 shows strong efficacy in treating Alzheimer's Disease Agitation, with significant CMAI score reductions in multiple Phase 3 trials. The FDA has greenlit Axsome to submit an sNDA for AXS-05 without requiring new trials, based on robust existing data. AXS-05 demonstrates a favorable safety profile with low discontinuation rates due to adverse events, unlike competitors such as AVP-786 and brexpiprazole.

AXIS Capital gains from a well-performing specialty insurance, reinsurance as well as the accident and health portfolio.